MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:40Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Corticosteroids]]
			[[Category:Glucocorticoids]]
			[[Category:Inhaled corticosteroids]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #272

2026-05-23T04:08:52Z

parser-claude batch MedTemplate pre-fill, Top 300 #272

New page

{{MedTemplate
| generic = Mometasone furoate
| brand = Nasonex (intranasal), Asmanex (inhaled), Elocon (topical), Sinuva (sinus implant); with formoterol as Dulera
| structure =
| classes = [[:Category:Corticosteroids|Corticosteroid]], [[:Category:Glucocorticoids|Glucocorticoid]], [[:Category:Inhaled_corticosteroids|Inhaled corticosteroid (ICS)]]
| uses = <vote slug="allergic-rhinitis-use">Allergic rhinitis (intranasal)</vote>, <vote slug="nasal-polyps-use">Nasal polyps (intranasal, sinus implant)</vote>, <vote slug="asthma-controller-use">Asthma controller (inhaled)</vote>, <vote slug="topical-dermatitis-use">Inflammatory dermatoses (topical)</vote>
| starting_dose = Intranasal Nasonex 2 sprays/nostril daily (50 mcg/spray); inhaled Asmanex 220 mcg DPI 1-2 inhalations daily/BID; topical Elocon 0.1% cream daily
| preparations = Nasonex 50 mcg/actuation intranasal; Asmanex HFA MDI 100/200 mcg; Asmanex Twisthaler DPI 110/220 mcg; Elocon 0.1% cream/ointment/lotion; Sinuva sinus implant; Dulera (with formoterol)
| fda_max = Intranasal 200 mcg/d (adults); inhaled 880 mcg/d
| pill_id =
| routes = Intranasal, inhaled, topical, intranasal sinus implant
| onset = Intranasal: symptom relief 12-24 hours; inhaled: bronchial effect 1-2 weeks
| duration = 24 hours
| halflife = ~5 hours (plasma)<ref name="nasonex-label">FDA Prescribing Information, Nasonex (mometasone furoate), Organon/Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020762s048lbl.pdf</ref>
| bioavailability = Intranasal: <1% systemic; inhaled lung deposition with extensive first-pass clearance<ref name="nasonex-label" />
| pregnancy = Intranasal long considered acceptable; widely used in obstetric rhinitis.{{citation needed}}
| legal = OTC (Nasonex 24HR) and [[USLegal:Prescription only|Rx-only]] (other forms) in US
| mechanism = <vote slug="mometasone-mech-claim">Mometasone furoate is a high-affinity glucocorticoid receptor agonist with extensive hepatic first-pass clearance (CYP3A4) that minimizes systemic glucocorticoid exposure from inhaled, intranasal, or topical administration.</vote> Like other locally-acting corticosteroids, broadly suppresses inflammatory gene transcription; clinical onset is gradual for asthma controller use but rapid for allergic rhinitis. Once-daily intranasal dosing reflects strong receptor binding and slow tissue clearance<ref name="nasonex-label" />.
}}

== References ==
<references />

Mometasone - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #272